| 1410 |
National Cancer Institute |
Html |
en |
Endometrial Cancer Prevention (PDQ®)–Health Professional Version |
Expert-reviewed information summary about factors that may influence the risk of developing endometrial cancer and about research aimed at the prevention of this disease. |
| Surgical Adjuvant Breast | 0.47836 |
| Obstet Gynecol | 0.483376 |
| World Cancer Research | 0.452806 |
| endometrial carcinoma | 0.52954 |
| Engl J Med | 0.456388 |
| American Cancer Society | 0.497798 |
| Br J Cancer | 0.455416 |
| case-control study | 0.441437 |
| Int J Cancer | 0.478131 |
| early-stage breast cancer | 0.461817 |
| intentional weight loss | 0.529248 |
| breast cancer treatment | 0.473891 |
| breast cancer patients | 0.472714 |
| body mass index | 0.470175 |
| endometrial cases | 0.529694 |
| Cancer Causes Control | 0.452081 |
| Natl Cancer Inst | 0.529481 |
| lower endometrial cancer | 0.563354 |
| postmenopausal endometrial cancer | 0.554715 |
| modifiable risk factor | 0.44186 |
| endometrial cancer | 0.948645 |
| invasive breast cancer | 0.472622 |
| Cancer Treat Rep | 0.454232 |
| et al. | 0.498732 |
|
| early breast cancer | 0.472532 |
| tamoxifen-treated breast cancer | 0.462067 |
| nonpolyposis colorectal cancer | 0.457467 |
| endometrial cancer cases | 0.601622 |
| polycystic ovarian syndrome | 0.445837 |
| Cancer Epidemiol Biomarkers | 0.47249 |
| endometrial cancer risk | 0.82277 |
| Cancer Facts | 0.44862 |
| PUBMED Abstract | 0.515106 |
| Nutr Cancer | 0.444116 |
| widespread endometrial cancer | 0.555715 |
| Epidemiol Biomarkers Prev | 0.442397 |
| endometrial cancer incidence | 0.612962 |
| Breast Cancer Prevention | 0.475561 |
| African American women | 0.440785 |
| invasive gynecologic cancer | 0.464853 |
| postmenopausal women | 0.497969 |
| Abstract | 0.52778 |
| breast cancer | 0.526041 |
| adjuvant tamoxifen | 0.441172 |
| physical activity | 0.445711 |
| Breast Cancer Study | 0.467445 |
| breast cancer incidence | 0.479289 |
| National Surgical Adjuvant | 0.475167 |
|
CLICK HERE |
| 1513 |
National Cancer Institute |
Html |
en |
Pancreatic Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of pancreatic cancer. |
| pancreatic carcinoma E6201 | 0.398831 |
| unresectable pancreatic carcinoma | 0.359985 |
| pancreatic malignancy | 0.311753 |
| Engl J Med | 0.337007 |
| Ann Surg | 0.317423 |
| German CONKO-study group | 0.318318 |
| phase iii trial | 0.413157 |
| pancreatic tumors | 0.328586 |
| der Schelling GP | 0.325496 |
| randomized phase | 0.350612 |
| advanced pancreatic adenocarcinoma | 0.470438 |
| randomized trial | 0.376847 |
| patients | 0.470655 |
| investigational new drug | 0.321651 |
| Cooperative Oncology Group | 0.454021 |
| van der Schelling | 0.325555 |
| Moore MJ | 0.343635 |
| fixed-dose rate infusion | 0.313379 |
| pancreatic carcinoma | 0.542646 |
| Ann Oncol | 0.304631 |
| et al. | 0.690156 |
| Best supportive care | 0.315629 |
| study | 0.356854 |
| Expandable metal stents | 0.329142 |
|
| phase ii trial | 0.320548 |
| Hammel et al. | 0.336299 |
| Oncology Group study | 0.328761 |
| Clinical Trials Group | 0.319844 |
| gemcitabine-based induction chemotherapy | 0.328647 |
| National Cancer Institute | 0.337583 |
| den Bosch RP | 0.325608 |
| advanced unresectable pancreatic | 0.366836 |
| metastatic pancreatic cancer | 0.353118 |
| advanced pancreatic cancer | 0.926655 |
| advanced pancreatic carcinoma | 0.404683 |
| unresectable periampullary adenocarcinoma | 0.332936 |
| first-line therapy | 0.306838 |
| van den Bosch | 0.324595 |
| refractory pancreatic cancer | 0.407704 |
| advanced pancreas cancer | 0.35576 |
| Abstract | 0.559395 |
| Clin Oncol | 0.91428 |
| unresectable pancreatic cancer | 0.410252 |
| Canada Clinical Trials | 0.318756 |
| Eastern Cooperative Oncology | 0.46104 |
| drug treatment program | 0.320206 |
| gemcitabine | 0.380059 |
| active chemotherapy regimens | 0.332336 |
|
CLICK HERE |
| 1522 |
National Cancer Institute |
Html |
en |
Childhood Brain Stem Glioma Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of childhood brain stem glioma. |
| PDQ Childhood Brain | 0.262624 |
| cancer treatment | 0.317391 |
| new cancer cells | 0.250632 |
| brain stem glioma | 0.990842 |
| metastatic brain tumors | 0.262145 |
| type | 0.250835 |
| PDQ cancer information | 0.305049 |
| clinical trial search | 0.257718 |
| brain tumors | 0.389165 |
| children | 0.259907 |
| clinical trials | 0.541127 |
| health care providers | 0.255221 |
| Pediatric Treatment Editorial | 0.256101 |
| cancer information summary | 0.282392 |
| clinical trial | 0.361183 |
| patients | 0.252235 |
| NCI PDQ cancer | 0.25809 |
| radiation therapy | 0.3037 |
| Treatment Editorial Board | 0.258484 |
| intrinsic pontine glioma | 0.314731 |
| focal childhood brain | 0.250848 |
| late effects | 0.256779 |
| treatment | 0.494086 |
| focal glioma | 0.286058 |
| cancer cells | 0.359639 |
|
| brain stem gliomas | 0.410944 |
| primary brain tumors | 0.262357 |
| PDQ Pediatric Treatment | 0.253085 |
| signs | 0.25352 |
| Benign brain tumors | 0.261631 |
| treatment clinical trials | 0.275821 |
| National Cancer Institute | 0.282821 |
| following PDQ treatment | 0.270231 |
| effects cancer treatment | 0.263814 |
| new treatment | 0.290537 |
| childhood cancer information | 0.253956 |
| childhood brain tumors | 0.305915 |
| BRAF kinase | 0.259925 |
| treatment clinical trial | 0.25851 |
| PDQ summary | 0.250138 |
| Malignant brain tumors | 0.261555 |
| cancer clinical trials | 0.275926 |
| focal brain stem | 0.331856 |
| treatment options | 0.261824 |
| brain tissue | 0.259205 |
| cancer | 0.498153 |
| standard treatment | 0.287654 |
| BRAF kinase inhibitor | 0.253173 |
| childhood brain stem | 0.659927 |
|
CLICK HERE |
| 1545 |
National Cancer Institute |
Html |
en |
Adult Hodgkin Lymphoma Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of adult Hodgkin lymphoma. |
| red blood cells | 0.404993 |
| cancer treatment | 0.406441 |
| body | 0.406679 |
| PDQ cancer information | 0.415705 |
| unfavorable Hodgkin lymphoma | 0.403766 |
| Non-Hodgkin Lymphoma Treatment | 0.396504 |
| clinical trial search | 0.387461 |
| pregnant women | 0.365816 |
| favorable Hodgkin lymphoma | 0.403909 |
| white blood cells | 0.390827 |
| favorable adult Hodgkin | 0.379079 |
| unfavorable adult Hodgkin | 0.379392 |
| clinical trials | 0.634552 |
| lymph nodes | 0.463894 |
| cancer information summary | 0.39389 |
| clinical trial | 0.489293 |
| stem cell transplant | 0.415484 |
| recurrent Hodgkin lymphoma | 0.402776 |
| adult hodgkin lymphoma | 0.802336 |
| patients | 0.379207 |
| blood cells | 0.446195 |
| weight loss | 0.391968 |
| NCI PDQ cancer | 0.365284 |
| radiation therapy | 0.587067 |
| Nodular sclerosing Hodgkin | 0.384149 |
|
| lymph node groups | 0.460532 |
| treatment | 0.56475 |
| night sweats | 0.39371 |
| Hodgkin Lymphoma Treatment | 0.422215 |
| cancer cells | 0.401875 |
| cellularity Hodgkin lymphoma | 0.419706 |
| swollen lymph nodes | 0.429808 |
| treatment clinical trials | 0.386111 |
| National Cancer Institute | 0.39221 |
| lymph vessels | 0.383555 |
| new treatment | 0.393163 |
| advanced hodgkin lymphoma | 0.435901 |
| Hodgkin lymphomas | 0.368401 |
| classical Hodgkin lymphoma | 0.419308 |
| bone marrow | 0.427904 |
| depletion Hodgkin lymphoma | 0.419209 |
| sedimentation rate | 0.371778 |
| hodgkin lymphoma | 0.94955 |
| cancer clinical trials | 0.401646 |
| stage | 0.410094 |
| Combination chemotherapy | 0.415703 |
| cancer | 0.682215 |
| information | 0.416232 |
| appropriate cancer treatment | 0.37213 |
|
CLICK HERE |
| 1621 |
National Cancer Institute |
Html |
en |
Ewing Sarcoma Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of Ewing sarcoma. |
| cancer treatment | 0.289749 |
| malignant tumor cells | 0.276208 |
| soft tissue | 0.253817 |
| body | 0.332426 |
| type | 0.219713 |
| chemotherapy | 0.237331 |
| treatments | 0.202586 |
| PDQ cancer information | 0.292839 |
| clinical trial search | 0.246556 |
| extraosseous Ewing sarcoma | 0.264218 |
| Ewing sarcoma spreads | 0.243807 |
| clinical trials | 0.704097 |
| Pediatric Treatment Editorial | 0.209616 |
| nearby lymph nodes | 0.208892 |
| cancer information summary | 0.25517 |
| clinical trial | 0.374839 |
| recurrent Ewing sarcoma | 0.335434 |
| stage Ewing sarcoma | 0.262403 |
| patients | 0.209976 |
| Soft Tissue Sarcoma | 0.20334 |
| childhood Ewing sarcoma | 0.227663 |
| CAR T-cell therapy | 0.238653 |
| NCI PDQ cancer | 0.207565 |
| Ewing sarcoma family | 0.264166 |
| radiation therapy | 0.525383 |
|
| Treatment Editorial Board | 0.214583 |
| treatment | 0.586815 |
| Ewing sarcoma | 0.925686 |
| Ewing sarcoma cells | 0.277555 |
| NCI-supported cancer | 0.206887 |
| cancer cells | 0.457951 |
| metastatic Ewing sarcoma | 0.365401 |
| specific cancer cells | 0.219988 |
| patient | 0.217481 |
| treatment clinical trials | 0.236708 |
| National Cancer Institute | 0.256904 |
| initial treatment | 0.212474 |
| effects cancer treatment | 0.221598 |
| new treatment | 0.271508 |
| bone | 0.246041 |
| metastatic tumor | 0.210193 |
| bone marrow | 0.235686 |
| Ewing tumor | 0.226375 |
| cancer clinical trials | 0.279951 |
| stem cell rescue | 0.32512 |
| tumor | 0.434783 |
| High-dose chemotherapy | 0.218893 |
| cancer | 0.820936 |
| standard treatment | 0.227171 |
|
CLICK HERE |
| 1718 |
National Cancer Institute |
Html |
en |
Pap and HPV Testing |
A fact sheet that describes the Pap and HPV tests, possible results from those tests, and the link between HPV and cervical cancer. |
| Pap test results | 0.318639 |
| precancerous cervical lesions | 0.292159 |
| squamous cells | 0.289348 |
| high-risk HPV | 0.671741 |
| First-line HPV testing | 0.290741 |
| squamous cell abnormalities | 0.296427 |
| primary HPV screening | 0.318981 |
| cervical screening | 0.408649 |
| glandular cell abnormalities | 0.323902 |
| professional cervical cancer | 0.287037 |
| cervical cells | 0.449089 |
| Pap test | 0.978312 |
| HPV testing | 0.403472 |
| frequent cervical screening | 0.280097 |
| cell abnormalities | 0.445026 |
| HPV test | 0.442688 |
| negative HPV test | 0.307642 |
| cervical cancer screening | 0.819575 |
| positive HPV test | 0.337496 |
| cervical cancer | 0.958343 |
| HPV DNA test | 0.30151 |
| Pap cytology test | 0.279358 |
| early cervical cancers | 0.308324 |
| HPV infections | 0.362202 |
|
| HPV test results | 0.327074 |
| abnormal cells | 0.314778 |
| abnormal cervical cells | 0.343301 |
| precancerous cervical lesion | 0.309268 |
| HPV | 0.765136 |
| Pap test result | 0.433853 |
| different HPV tests | 0.296834 |
| cervical cell abnormalities | 0.361261 |
| cobas HPV test | 0.304363 |
| high-risk HPV types | 0.661339 |
| additional high-risk HPV | 0.303577 |
| new cervical cancers | 0.27692 |
| high-risk HPV type | 0.405337 |
| cervical cancer risk | 0.324311 |
| HPV cotesting | 0.335213 |
| liquid-based Pap cytology | 0.286767 |
| future cervical cancer | 0.287194 |
| abnormal Pap test | 0.300522 |
| HPV infection | 0.371378 |
| cells | 0.464647 |
| regular cervical screening | 0.330087 |
| Routine cervical screening | 0.314661 |
| Pap testing | 0.293059 |
| cell changes | 0.293167 |
|
CLICK HERE |
| 1935 |
National Cancer Institute |
Html |
es |
Tratamiento del ependimoma infantil (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del ependimoma infantil. |
| radiocirugÃa estereotáctica | 0.685192 |
| siguientes procedimientos | 0.332065 |
| efectos secundarios meses | 0.562136 |
| siguientes áreas | 0.378745 |
| huesos dorsales | 0.375848 |
| general recidiva | 0.34956 |
| efectos tardÃos | 0.729968 |
| PDQ Efectos tardÃos | 0.453185 |
| cabo irm | 0.352274 |
| lÃquido cefalorraquÃdeo | 0.982409 |
| punción espinal.Ampliar | 0.373407 |
| estudio clÃnico | 0.337757 |
| National Cancer Institute | 0.329628 |
|
| siguientes riesgos | 0.321782 |
| Instituto Nacional | 0.357335 |
| PDQ Tratamiento | 0.392525 |
| determinados cambios | 0.326515 |
| gen rela | 0.670707 |
| nuevos tipos | 0.348217 |
| siguientes factores | 0.370167 |
| sistema nervioso central | 0.663463 |
| Physician Data Query | 0.423559 |
| segura.ampliar craneotomÃa | 0.353248 |
| cuánto tumor | 0.478632 |
| siguientes sumarios | 0.438618 |
|
CLICK HERE |
| 3438 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de estómago (gástrico) (PDQ®)–Versión para profesionales de salud |
Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de estómago (gástrico). |
| Offerhaus J | 0.113586 |
| Cancer Res Clin | 0.264444 |
| Cancer high-risk subjects | 0.263357 |
| mass screening | 0.365942 |
| Leung WK | 0.124317 |
| Kobayashi K | 0.11932 |
| American Cancer Society | 0.823817 |
| detección versus | 0.189954 |
| case-control study | 0.112022 |
| Tytgat GN | 0.125733 |
| CA Cancer | 0.258236 |
| Instituto Nacional | 0.144846 |
| PDQ Exámenes | 0.215492 |
| prospectively followed chinese | 0.229607 |
| Estados Unidos | 0.202827 |
| Yanaoka K | 0.108053 |
| biological agents | 0.104643 |
| Morson BC | 0.118473 |
| high risk | 0.121936 |
| repeated endoscopic screens | 0.228776 |
| Lancet Oncol | 0.24929 |
| mass screening program | 0.337333 |
| mass survey | 0.121584 |
| Gastrointestinal Tract | 0.130066 |
| Ma JL | 0.109737 |
|
| mass screening techniques | 0.150063 |
| Precancerous Lesions | 0.123357 |
| Barbara L | 0.103989 |
| Cancer Facts | 0.263557 |
| Pfeiffer R | 0.11257 |
| Costa Rica | 0.0971337 |
| detección darán | 0.220411 |
| Mathus-Vliegen EM | 0.121366 |
| Ubukata T | 0.120185 |
| National Cancer Institute | 0.793771 |
| Oka M | 0.099234 |
| gastric carcinoma | 0.217462 |
| Endoscopic screening during | 0.138672 |
| serum pepsinogen concentrations | 0.241325 |
| New York | 0.185957 |
| Clin Oncol | 0.132653 |
| Kitahara F | 0.112823 |
| Sherlock P | 0.239085 |
| X-ray screening seems | 0.130764 |
| serum pepsinogen | 0.612986 |
| using serum pepsinogen | 0.482271 |
| Sato T | 0.127922 |
| stomach cancer | 0.944477 |
| Wu MS | 0.109301 |
|
CLICK HERE |
| 3576 |
National Cancer Institute |
Html |
en |
Cancer Prevention Research |
NCI’s prevention research has a broad focus, from identifying environmental and lifestyle factors that influence cancer risk to studying the biology of how cancer develops and studying ways to disseminate prevention interventions. |
| potential preventive therapies | 0.441911 |
| cancer prevention trials | 0.552513 |
| Drug Development Program | 0.440287 |
| PREVENT Cancer Preclinical | 0.524374 |
| higher cancer rates | 0.5328 |
| public health imperative | 0.449962 |
| Tobacco Control Research | 0.447635 |
| tobacco control programs | 0.463087 |
| invasive cancer | 0.460548 |
| specific population groups | 0.436493 |
| behavioral risk factors | 0.665388 |
| cancer care | 0.47747 |
| NCI’s Division | 0.485356 |
| cervical cancer | 0.456337 |
| Reduce Cancer Health | 0.518587 |
| FDA-approved HPV vaccines—work | 0.439068 |
| NCI’s Center | 0.488421 |
| Cancer Epidemiology | 0.455548 |
| prevention-focused clinical studies | 0.444916 |
| cancer health disparities | 0.673431 |
| Cancer Control | 0.456877 |
| risk reduction | 0.469434 |
| cancer screening | 0.48636 |
| cancer prevention | 0.875489 |
|
| United States | 0.669252 |
| new cancer prevention | 0.553181 |
| annual cancer-related deaths | 0.450355 |
| Cancer Research | 0.477162 |
| studies | 0.468685 |
| HPV-associated cancer | 0.458082 |
| cancer researchers | 0.479223 |
| substantially increased risk | 0.487266 |
| prevention research efforts | 0.4695 |
| HPV vaccine trials | 0.440028 |
| NCI Community Oncology | 0.488471 |
| new preventive therapy | 0.454621 |
| cancer development | 0.485138 |
| people | 0.446203 |
| cancer prevention research | 0.671334 |
| cancer disparities | 0.497724 |
| physical activity | 0.439301 |
| bivalent HPV vaccine | 0.436545 |
| Cancer Prevention Clinical | 0.54727 |
| NCI Cohort Consortium | 0.479534 |
| cancer risk | 0.971388 |
| cancer | 0.983944 |
| cancer incidence | 0.537166 |
| genome-wide association studies | 0.438797 |
|
CLICK HERE |
| 15877 |
National Cancer Institute |
Html |
es |
Antineoplastones (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos sobre los antineoplastones como tratamiento para personas con cáncer. |
| corta duración | 0.52325 |
| suficientes antineoplastones | 0.570315 |
| Centro Nacional | 0.534282 |
| New Hampshire Avenue | 0.523956 |
| cabo ensayos | 0.607081 |
| Drug Administration | 0.514884 |
| antineoplastones a10 | 0.621411 |
| NCI Best Case | 0.546794 |
| siguientes tipos | 0.528576 |
| PDQ Antineoplastones | 0.580269 |
| datos bibliográficos pubmed | 0.525907 |
| siguientes preguntas | 0.515649 |
| fase ii | 0.701787 |
| células tumorales animales | 0.553458 |
| National Cancer Institute | 0.529942 |
| siguientes riesgos | 0.520138 |
| seguro médico | 0.513988 |
|
| Instituto Nacional | 0.710175 |
| Salud Complementaria | 0.553301 |
| Visuals Online | 0.517781 |
| complementarias revisa | 0.52541 |
| Physician Data Query | 0.604461 |
| antineoplastones a2 | 0.575169 |
| Estados Unidos | 0.855832 |
| corto plazo | 0.520833 |
| libre uso | 0.517405 |
| página manejo | 0.516526 |
| ¿El tratamiento | 0.536286 |
| ClÃnica Mayo | 0.524069 |
| ¿Los beneficios | 0.515122 |
| juntos cam | 0.514422 |
| Series Program | 0.514906 |
| medicina complementaria | 0.99587 |
|
CLICK HERE |